<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123405</url>
  </required_header>
  <id_info>
    <org_study_id>2018-08-EFT-1</org_study_id>
    <secondary_id>2019-000060-20</secondary_id>
    <nct_id>NCT04123405</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis</brief_title>
  <official_title>Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis: a Prospective, Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will be conducted as a prospective, randomized, multinational, multicenter,
      double-blind study in 4 parallel groups of patients. Approximately 900 patients with acute,
      uncomplicated rhinosinusitis will be randomized.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The test product (Acetylcysteine 600 mg effervescent tablet) is registered in many EU as well
      as non-EU countries for the secretolytic therapy in acute and chronic bronchopulmonary
      diseases.

      The primary aim of this trial is to assess the efficacy of three different total daily doses
      of the investigational product containing 600 mg acetylcysteine per effervescent tablet
      compared to placebo for the treatment of acute uncomplicated rhinosinusitis.

      The trial design was chosen according to the recommendation of the current guidelines
      EMA/CHMP/ICH/135/19953 and CPMP/ICH/291/95
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 7, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 24, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in the daily Major Symptoms Score (MSS) over the entire treatment period</measure>
    <time_frame>15 days</time_frame>
    <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure) and has been employed as primary efficacy criterion in several clinical trials.
Assessment of symptom severity. The user will rate the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The daily outcome will be the sum all symptom scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of action</measure>
    <time_frame>15 days</time_frame>
    <description>Time to onset of action is defined as first day of active treatment on which MSS shows statistically significant difference from placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSS development over the course of the study</measure>
    <time_frame>daily from Baseline to Day 15</time_frame>
    <description>The MSS combines the 5 most relevant symptoms of rhinosinusitis based on expert clinician recommendations (rhinorrhea/ anterior discharge, postnasal drip, nasal congestion, headache, and facial pain/pressure) and has been employed as primary efficacy criterion in several clinical trials.
Assessment of symptom severity. The user will rate the severity of each of the five symptoms of the MSS using a four-point rating scale of increasing severity (0 = none/not present, 1 = mild, 2 = moderate, 3 = severe). The daily outcome will be the sum all symptom scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SNOT-22 by visit and changes versus baseline</measure>
    <time_frame>Baseline (Day 1), Day 8, Day 15</time_frame>
    <description>The 22-item Sino-Nasal Outcome Test (SNOT-22) is a commonly utilized outcome measure for rhinosinusitis. 22 items are assessed according to their severity. Additionally five most important items can be selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders and non-responders</measure>
    <time_frame>Day 4, Day 7, Day 10, Day 15</time_frame>
    <description>Percentage of responders and non-responders to treatment is based on the assessment of overall response to treatment by the investigator</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>acetylcysteine 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg acetylcysteine: one tablet test product plus three tablets placebo per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acetylcysteine 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two tablets test product plus two tablets placebo per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acetylcysteine 2400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>four tablets test product per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>four tablets placebo per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylcysteine</intervention_name>
    <description>600 mg tablet</description>
    <arm_group_label>acetylcysteine 1200 mg</arm_group_label>
    <arm_group_label>acetylcysteine 2400 mg</arm_group_label>
    <arm_group_label>acetylcysteine 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to acetylcysteine</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>acetylcysteine 1200 mg</arm_group_label>
    <arm_group_label>acetylcysteine 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects aged between 14 and 75 years inclusive on the date of consent

          2. Diagnosis of acute, uncomplicated rhinosinusitis defined at screening visit 1 and at
             Visit 2 as:

               1. major symptom score (MSS) assessed by the patient ≥8 and ≤12 points for the
                  following: rhinorrhea/ anterior discharge, postnasal drip, nasal congestion,
                  headache, and facial pain/pressure, whereupon the nasal congestion is mandatory
                  and no more than 3 of the 5 symptoms are rated as severe

               2. individual score for facial pain/pressure ≥1 (mild) and ≤2 (moderate)

               3. presence of symptoms ≤3 days prior to screening visit

          3. For adults (≥18 years): Informed consent to participate in the trial provided in
             written form; For adolescents (≥14 - &lt;18 years): own subject informed consent/ assent
             to participate in the trial and the informed consent from all parent(s)/ legal
             guardian(s) provided in written form.

        Exclusion Criteria:

          1. History of hypersensitivity or intolerance to the active substance or any of the
             excipients of the trial medication

          2. Patient with history of hereditary fructose intolerance, galactose intolerance,
             lactase deficiency or glucose-galactose malabsorption

          3. Chronic rhinosinusitis (symptoms lasting longer than 3 months)

          4. Subjects who have undergone sinus or nasal surgery for chronic rhinosinusitis in the 6
             months prior to screening visit

          5. Sinus lavage within 7 days prior to screening visit

          6. Odontogenic rhinosinusitis

          7. Allergic (perennial or seasonal) rhinitis

          8. Bronchial asthma or chronic obstructive pulmonary disease

          9. Nasal polyposis or clinically relevant nasal septum deviation

         10. Concomitant otitis

         11. Intranasal or systemic use of corticosteroids within 30 days prior to screening visit

         12. Intranasal or systemic use of antibiotics within 30 days prior to screening visit

         13. Use of nasal decongestants within 2 days prior to screening visit

         14. Concomitant treatment of common cold-like symptoms within 7 days prior to screening
             visit with any of the following:

               1. Analgesics

               2. Non-steroidal anti-inflammatory drugs

               3. Antihistamines

         15. Concomitant use of intranasal saline irrigation

         16. Use of immunosuppressive agents within 30 days prior to screening visit

         17. Immunocompromised state

         18. Suspicion for acute bacterial rhinosinusitis (defined as presence of purulence for 3
             to 4 days with fever ≥ 38.3°C)

         19. Pregnant or breast-feeding female patient

         20. Female patient of childbearing potential (not surgically sterilized/hysterectomized or
             postmenopausal for at least 1 year) who is not currently using (documented at
             screening visit) and not willing to use medically reliable methods of contraception
             for the entire trial duration such as oral, injectable or implantable contraceptives,
             intrauterine contraceptive devices (IUD), sexual abstinence or vasectomized partner

         21. Any other condition of the patient (e.g. serious or unstable medical or psychological
             condition, acute psychosis) that in the opinion of the investigator may compromise
             evaluation of the trial treatment or may jeopardize patient's safety, compliance or
             adherence to protocol requirements

         22. Participation in ANY research study involving another investigational medicinal
             product (IMP) within 30 days prior to screening visit, or simultaneous participation
             in another clinical study or previous participation in present study

         23. Suspected alcohol/ drug dependence or abuse (including heavy smoking: ≥ 20 cigarettes
             daily)

         24. Use of snuff tobacco

         25. Legal incapacity and/or other circumstances rendering the patient unable to understand
             the nature, scope and possible consequences of the trial

         26. Subjects who are known or suspected:

               -  not to comply with the trial directives

               -  not to be reliable or trustworthy

               -  to be a dependent person, e.g. a relative, family member, or member/employee of
                  the investigator's or sponsor's staff

               -  subject is in custody or submitted to an institution due to a judicial order.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandoz</last_name>
    <role>Study Director</role>
    <affiliation>Sandoz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41-61-3241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1408</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1510</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Yambol</city>
        <zip>8600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Arnsberg</city>
        <zip>59759</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Dreieich</city>
        <zip>63303</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01139</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Erfurt</city>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2004</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2009</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2012</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2023</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2028</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2032</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2038</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2051</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <zip>2064</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Chișinău</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Orhei</city>
        <zip>3005</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115409</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119416</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119571</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>123098</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>142190</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192177</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192283</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193232</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194334</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195197</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196158</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197372</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Vsevolozhsk</city>
        <zip>188643</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>15054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute uncomplicated rhinosinusitis, acetylcysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

